Does tirzepatide cure sleep apnoea?

The trials report large reductions in apnoea-hypopnoea index, not elimination. Mean AHI fell substantially but participants were not reported as free of the condition.

Is the benefit just from weight loss?

Weight reduction is the most plausible route, given the mechanical relationship between soft tissue around the airway and apnoea severity. The trials were not designed to separate the two.

Why were there two studies?

One enrolled participants using positive airway pressure therapy and one did not. A drug's effect on top of an existing effective treatment is a different question from its effect alone.

GLP-1 & Incretin Science

SURMOUNT-OSA: Tirzepatide in Obstructive Sleep Apnoea

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

SURMOUNT-OSA tested tirzepatide in adults with moderate-to-severe obstructive sleep apnoea and obesity across two 52-week studies. In participants not using positive airway pressure, mean apnoea-hypopnoea index fell 27.4 events per hour against 4.8 on placebo — a 55.0% reduction against 5.0%.

Key facts

Trial: SURMOUNT-OSA, two 52-week studies
Publication: NEJM, October 2024 (PMID 38912654)
Study 1 population: Not using PAP therapy
Study 1 AHI reduction: 27.4 events/hour vs 4.8 placebo
Study 1 percentage: 55.0% vs 5.0%
Study 2 (on PAP): 30.4 events/hour vs 6.0 placebo
Weight reduction: 18.1% vs 1.3% (Study 1)
Estimand: Efficacy estimand

Why sleep apnoea is a coherent target

Obstructive sleep apnoea occurs when the upper airway collapses repeatedly during sleep. Excess soft tissue around the airway is one contributor, and body weight is strongly associated with severity. A compound producing 18% weight reduction therefore has a plausible mechanical route to reducing apnoea severity — this is not an unexpected pleiotropic effect but a fairly direct consequence.

What AHI measures

The apnoea-hypopnoea index counts breathing interruptions per hour of sleep. Roughly, 5 to 15 is mild, 15 to 30 moderate and above 30 severe. Because it is an event rate rather than a symptom score, a change of 27.4 events per hour is a large absolute movement — enough to shift a participant across severity categories rather than within one.

The two studies and why they were split

Study 1 enrolled participants not using positive airway pressure therapy; Study 2 enrolled those using PAP and continuing it. Splitting them matters because PAP is an effective existing treatment, and a drug's contribution on top of PAP is a different question from its effect in people not using it. Study 2 reported a mean AHI reduction of 30.4 events per hour against 6.0 on placebo.

What else moved

Beyond AHI and body weight, the published results reported reductions in hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure, alongside improvement in sleep-related patient-reported outcomes. The last of those matters most clinically: an event-rate improvement that patients do not notice would be a weaker result than one they report feeling.

The estimand, again

The reported figures are for the efficacy estimand — participants adhering to treatment — which the release states explicitly. As with CagriSema's 22.7% and SURMOUNT-1's 22.5%, quoting the figure without naming the estimand overstates what a treatment-policy analysis would show. The consistency of this pattern across the field is why it is worth checking every time.

Why this approval mattered

It moved an incretin into a non-metabolic indication with an objective, instrument-measured endpoint. AHI is recorded by polysomnography, not reported by the participant, which makes it harder to attribute to expectation effects than a symptom questionnaire. That strengthens the broader case that weight reduction at this magnitude produces measurable downstream change.

Quick reference

Endpoint (52 wks)	Tirzepatide	Placebo
AHI reduction, Study 1	27.4 events/hr	4.8 events/hr
AHI percentage, Study 1	55.0%	5.0%
AHI reduction, Study 2	30.4 events/hr	6.0 events/hr
Body weight, Study 1	−18.1%	−1.3%

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does tirzepatide cure sleep apnoea?: The trials report large reductions in apnoea-hypopnoea index, not elimination. Mean AHI fell substantially but participants were not reported as free of the condition.
Is the benefit just from weight loss?: Weight reduction is the most plausible route, given the mechanical relationship between soft tissue around the airway and apnoea severity. The trials were not designed to separate the two.
Why were there two studies?: One enrolled participants using positive airway pressure therapy and one did not. A drug's effect on top of an existing effective treatment is a different question from its effect alone.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum